Grace Therapeutics, Inc.
GRCE· Nasdaq
GRCEGrace Therapeutics, Inc.
Filed Nov 13, 2025 · 10-Q · 44 days after period end · 0001140361-25-041804
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$938.00K | -$3.43M | -$3.27M | -$4.93M |
| EPS Diluted | -$0.06 | -$0.30 | -$0.43 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Nov 13, 2025 · 44 d after period end
